ProPhase LabsPRPH -4.61% EBITDA Margin % is 164.92% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 85.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ProPhase Labs's EBITDA for the
three
months ended in Dec. 2025 was $1.29 Mil. ProPhase Labs's Revenue for the
three
months ended in Dec. 2025 was $0.78 Mil. Therefore, ProPhase Labs's EBITDA margin for the quarter that ended in Dec. 2025 was 164.92%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ProPhase Labs EBITDA Margin % Related Terms
ProPhase Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NSTM, IDTA, IVRO: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a EBITDA Margin % of 164.92% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #174 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 85.3%.
Is ProPhase Labs' EBITDA Margin % too high?
ProPhase Labs' current EBITDA Margin % is 164.92%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. ProPhase Labs' value of 164.92% is 3071.5% above this industry median. Based on the distribution chart, ProPhase Labs ranks #174 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' EBITDA Margin % compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #174 out of 204 companies for EBITDA Margin %. This places ProPhase Labs in the lower half of its industry. The industry median EBITDA Margin % is 5.20. ProPhase Labs' value of 164.92% is 3071.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current EBITDA Margin % of 164.92% is 3071.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current EBITDA Margin % is 164.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current EBITDA Margin % is 164.92% and 3071.5% above the Medical Diagnostics & Research industry median of 5.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current EBITDA Margin % is 164.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 